1128 J. Am. Chem. Soc., Vol. 121, No. 6, 1999
Herman et al.
The crude product was recrystallized from 3:1 ethyl acetate/hexanes
to yield 5 as a fluffy white foam: 6.1 g, 42% yield; TLC (2:3 hexanes/
ethyl acetate v/v) Rf 0.6 1H NMR (DMSO-d6) δ 9.07 (s, 1 H), 7.90 (d,
2 H, J ) 7.6 Hz), 7.61 (t, 1 H, J ) 7.2 Hz), 7.50 (t, 2 H, J ) 7.5 Hz),
7.31 (m, 4 H), 7.06 (s, 1 H), 6.62 (s, 1 H), 5.47 (s, 2 H), 5.16 (s, 2 H),
3.80 (s, 2 H), 3.76 (s, 3 H), 1.42 (s, 9H) 13C NMR (DMSO-d6) δ 193.1,
171.2, 160.6, 153.2, 135.7, 134.4, 130.1, 129.4, 128.5, 128.3, 123.7,
120.0, 119.0, 108.0, 79.0, 67.4, 65.1, 36.7, 28.6; FABMS m/e 506.205
(506.205 calcd for C28H30N2O7).
palladium acetate (330 mg, 37 °C, 10 min) followed by the addition of
ammonium formate (500 mg, 37 °C, 8 h). The reaction mixture was
then filtered to remove resin and diluted with 0.1% (wt/v) TFA (8 mL),
and the resulting solution was purified by reversed phase HPLC to
yield H2N-γ-ImPyPyPy-(R)Bocγ-ImPyPyPy-COOH as the trifluoroac-
1
etate salt: 4.2 mg, 10% recovery; H NMR (DMSO-d6) δ 10.36 (s, 1
H), 10.22 (s, 1 H), 10.14 (s, 1 H), 9.99 (s, 1 H), 9.97 (s, 2 H), 9.92 (s,
2 H), 7.97 (m, 1 H), 7.74 (br s 3 H), 7.45 (m, 1 H), 7.43 (s, 1 H), 7.42
(s, 1 H), 7.29 (s, 1 H), 7.26 (d, 1 H, J ) 1.7 Hz), 7.23 (m, 2 H), 7.17
(s, 1 H), 7.14 (s, 1 H), 7.12 (s, 1 H), 7.06 (m, 2 H), 6.95 (s, 1 H), 6.90
(s, 1 H), 6.83 (d, 1 H, J ) 1.3 Hz), 4.20 (m, 1 H), 3.94 (s, 6 H), 3.84
(m, 12 H), 3.81 (s, 3 H), 3.78 (s, 3 H), 3.22 (m, 2 H), 2.83 (quintet, 2
H, J ) 6.2 Hz), 2.41 (t, 2 H, J ) 6.9 Hz), 1.83 (m, 4 H), 1.38 (s, 9 H),
MALDI-TOF-MS (monoisotopic) [M + H] 1282.6 (1282.6 calcd for
C59H72N21O13).
Boc-Pyrrolyl-4-(oxymethyl)phenylacetic Acid (6) Zinc dust was
activated with 1 M HCl (aqueous) as described.17 Boc-Pyrrolyl-4-
(oxymethyl)phenylacetic acid phenacyl ester (3 g, 5.9 mmol) was
dissolved in 90 mL 4:1 acetic acid/water (v/v). Zinc dust (9.6 g, 147
mmol) was added and the reaction stirred for 18 h at room temperature.
The zinc was removed by filtration and the reaction mixture partitioned
between 200 mL of ethyl ether and 200 mL of water. The layers were
separated, the aqueous layer was extracted (ethyl ether, 1 × 200 mL),
and the combined ether layers were washed (water, 5 × 100 mL), dried
(sodium sulfate), concentrated in vacuo, and azeotroped (benzene, 6
× 100 mL). The crude acid product was purified by flash chromatog-
raphy (2:1 hexanes/ethyl acetate) to yield a yellow oil: 2.0 g, 86%
Cyclo-(γ-ImPyPyPy-(R)H2Nγ-ImPyPyPy-) (3). The amine-polya-
mide 12 (2.8 mg, 2.0 µmol) was dissolved in DMF (7 mL), and treated
with DPPA (12.5 µL) and K2CO3 (100 mg) for 3 h. The reaction mixture
was concentrated in vacuo, treated with TFA (3 mL, 1 h), and purified
by reversed phase HPLC to provide the trifluoroacetate salt of cyclo-
(γ-ImPyPyPy-(R)H2Nγ-ImPyPyPy) (3). Cyclo-(γ-ImPyPyPy-(R)H2Nγ-
ImPyPyPy) was recovered as a white powder upon lyophilization of
the appropriate fractions (1.0 mg, 38% recovery). MALDI-TOF-MS
(monoisotopic) [M + H] 1164.5 (1164.5 calcd for C54H62N21O10).
Cyclo-(γ-ImPyPyPy-(R)H2Nγ-PyPyPyPy) (4). The amine-polyamide
13 (7 mg, 5.0 µmol) was dissolved in DMF (7 mL), and treated with
DPPA (12.5 µL) and K2CO3 (100 mg) for 3 h. The reaction mixture
was concentrated in vacuo, treated with TFA (3 mL, 1 h), diluted to 8
mL with 0.1% (wt/v) TFA, and purified by reversed phase HPLC to
provide cyclo-(γ-ImPyPyPy-(R)H2Nγ-PyPyPyPy) (4). Cyclo-(γ-ImPy-
PyPy-(R)H2Nγ-PyPyPyPy) was recovered as a white powder upon
lyophilization of the appropriate fractions as the trifluoroacetate salt
(2.6 mg, 41% recovery). 1H NMR (DMSO-d6) δ 10.56 (s, 1 H), 10.26
(s, 1 H), 9.96 (s, 2 H), 9.95 (s, 3 H), 9.92 (s, 1 H), 8.27 (m, 4 H), 9.00
(m, 1 H), 7.45 (s, 1 H), 7.39 (s, 1 H), 7.38 (s, 1 H), 7.34 (s, 1 H), 7.29
(s, 1 H), 7.26 (s, 1 H), 7.25 (s, 1 H), 7.18 (s, 1 H), 7.08 (s, 1 H), 6.93
(m, 1 H), 6.91 (s, 1 H), 6.89 (s, 1 H), 6.85 (s, 2 H), 6.82 (s, 1 H), 5.31
(m, 1 H), 3.93 (s, 3 H), 3.85 (s, 3 H), 3.83 (m, 9 H), 3.80 (s, 3 H), 3.78
(s, 3 H), 3.76 (s, 3 H), 3.23 (m, 2 H), 2.72 (m, 2 H), 2.36 (m, 2 H),
1.97 (m, 4 H), 1.38 (s, 9 H), MALDI-TOF-MS (monoisotopic) [M +
H] 1163.4 (1163.5 calcd for C55H63N20O10).
Cyclo-(γ-ImPyPyPy-(R)EDTA‚Fe(II)γ-PyPyPyPy-) (4-E‚Fe(II)). Ex-
cess EDTA-dianhydride (180 mg) was dissolved in 1:1 DMSO/NMP
(1 mL) and DIEA (1 mL) by heating at 60 °C for 10 min. The
dianhydride solution was added to cyclo(γ-ImPyPyPy-(R)H2Nγ-PyPy-
PyPy-) (4) (1.3 mg, 1.0 µmol) dissolved in DMSO (1 mL). The mixture
was heated (60 °C, 2 h) and the remaining EDTA-dianhydride
hydrolyzed with 0.1M NaOH (2 mL, 60 °C, 15 min). Aqueous TFA
(0.1wt %/v) was added to adjust the total volume to 8 mL and the
solution purified directly by reversed phase HPLC to provide to cyclo-
(γ-ImPyPyPy-(R)EDTA‚Fe(II)γ-PyPyPyPy-) (4-E‚Fe(II)) as a white powder
upon lyophilization of the appropriate fractions: 0.25 mg, 18%
recovery; MALDI-TOF-MS (monoisotopic) [M + H] 1438.1 (1437.6
calcd for C65H77N22O17).
DNA Reagents and Materials. Enzymes were purchased from
Boehringer-Mannheim and used with their supplied buffers. Deoxy-
adenosine and thymidine 5′-[R-32P] triphosphates were obtained from
Amersham, and deoxyadenosine 5′-[γ-32P]triphosphate was purchased
from I. C. N. Sonicated, deproteinized calf thymus DNA was acquired
from Pharmacia. RNase free water was obtained from USB and used
for all footprinting reactions. All other reagents and materials were
used as received. All DNA manipulations were performed according
to standard protocols.22
Preparation of 3′- and 5′-End-Labeled Restriction Fragments.
The plasmid pJT8 was constructed as previously reported. pJT8 was
linearized with AflII and FspI restriction enzymes, then treated with
the Sequenase enzyme, deoxyadenosine 5′-R-32P]triphosphate, and
thymidine 5′-[R-32P]triphosphate for 3′ labeling. Alternatively, these
plasmids were linearized with AflII, treated with calf alkaline phos-
phatase, and then 5′-labeled with T4 polynucleotide kinase and
deoxyadenosine 5′-[γ-32P]triphosphate. The 5′-labeled fragment was
1
yield; TLC (ethyl acetate) Rf 0.7; H NMR (DMSO-d6) δ 9.06 (s, 1
H), 7.29 (d, 2 H, J ) 7.8 Hz), 7.21 (d, 2 H. J ) 7.8 Hz), 7.06 (s, 1 H),
6.6 (s, 1 H), 5.14 (s, 2 H), 3.74 (s, 3 H), 3.52 (s, 2 H), 1.38 (s, 9 H).
Boc-aminoacyl-Pyrrolyl-4-(oxymethyl)-Pam Resin (7). Boc-Pyr-
rolyl-4-(oxymethyl)phenylacetic acid (6) (1 g, 2.57 mmol) was dissolved
in 6.5 mL DMF. HOBt (382 mg, 2.8 mmol) followed by DCC (735
mg, 3.2 mmol) was added and the reaction mixture shaken for 4 h at
room temperature. The precipitated DCU was filtered and the reaction
mixture was added to 10 g aminomethyl-polystyrene resin (0.7 mmol/g
substitution) previously swollen for 30 min in DMF. DIEA (1 mL)
was added and the reaction shaken until the resin was determined by
the ninhydrin test and picric acid titration to be approximately 0.1
mmol/g substituted. The resin was washed with DMF, and the remaining
amine groups were capped by acetylation (2×) with excess acetic
anhyride capping solution (2:2:1 DMF/Ac2O/DIEA). The resin was
washed with DMF (1 × 20 mL), DCM (1 × 20 mL), and MeOH (1 ×
20 mL) and dried in vacuo.
H2N-γ-ImPyPyPy-(R)Bocγ-PyPyPyPy-COOH (13). Cbz-γ-ImPy-
PyPy-(R)Fmocγ-PyPyPyPy-Pam resin was synthesized in a stepwise
fashion by machine-assisted solid-phase methods from Boc-Py-Pam
resin (0.1 mmol/g). (R)-2-Fmoc-4-Boc-diaminobutyric acid (0.7 mmol)
was incorporated as previously described for Boc-γ-aminobutyric acid.
Cbzγ-ImPyPyPy-(R)Fmocγ-PyPyPyPy-Pam resin was placed in a glass
20-mL peptide synthesis vessel and treated with DMF (2 mL) followed
by piperidine (8 mL) and agitated (22 °C, 30 min). Cbzγ-ImPyPyPy-
(R)H2Nγ-PyPyPyPy-Pam resin was isolated by filtration and washed
sequentially with an excess of DMF, DCM, MeOH, and ethyl ether,
and the amine resin was dried in vacuo. Cbzγ-ImPyPyPy-(R)H2Nγ-
PyPyPyPy-Pam resin was then treated with 300 mg of Boc-anhydride
(2 mL DMF, 1 mL DIEA, 55 °C, 30 min) to provide Cbzγ-ImPyPyPy-
(R)Bocγ-PyPyPyPy-Pam resin. Palladium acetate (200 mg, 37 °C, 10
min) in 2 mL of DMF was added to a sample of the Boc-resin (200
mg, 0.09 mmol/gram), ammonium formate (500 mg) was then added,
and the reaction was allowed to shake for 8 h at 37 °C. The reaction
mixture was then filtered to remove resin and precipitated palladium
metal and diluted with 0.1% (wt/v) TFA (8 mL), and the resulting
solution was purified by reversed phase HPLC to yield the trifluoro-
acetate salt of H2N-γ-ImPyPyPy-(R)Bocγ-PyPyPyPy-COOH: 17 mg,
1
66% recovery; H NMR (DMSO-d6) δ 10.35 (s, 1 H), 9.98 (s, 2 H),
9.96 (s, 3 H), 9.92 (s, 2 H), 7.98 (m, 1 H), 7.75 (br s 3 H), 7.44 (m, 1
H), 7.42 (s, 1 H), 7.30 (s, 1 H), 7.26 (s, 1 H), 7.25 (m, 2 H), 7.18 (m,
2 H), 7.15 (d, 1 H, J ) 1.3 Hz), 7.13 (s, 1 H), 7.06 (m, 3 H), 6.96 (s,
1 H), 6.93 (s, 1 H), 6.90 (s, 1 H), 6.84 (d, 1 H, J ) 1.8 Hz), 4.07 (q,
1 H, J ) 6.0 Hz), 3.95 (s, 3 H), 3.84 (m, 15 H), 3.82 (s, 3 H), 3.79 (s,
3 H), 3.22 (m, 2 H), 2.81 (m, 2 H), 2.39 (t, 2 H, J ) 6.9 Hz), 1.83 (m,
4 H), 1.39 (s, 9 H), MALDI-TOF-MS (monoisotopic) [M + H] 1281.5
(1281.6 calcd for C60H73N20O13).
H2N-γ-ImPyPyPy-(R)Bocγ-ImPyPyPy-COOH (12). Cbz-γ-ImPy-
PyPy-(R)Boc-γ-ImPyPyPy-Pam resin was prepared as described for (13).
A sample of the Boc-resin (330 mg, 0.09 mmol/gram) was treated with